Duality Biotherapeutics, Inc.
Status: Publicly traded
Direct answer
Duality Biotherapeutics, Inc. is publicly traded on HKSE under the ticker 9606.HK.
Operating as a clinical-stage enterprise, Duality Biotherapeutics, Inc. concentrates on pioneering next-generation antibody-drug conjugate (ADC) therapies and proprietary duality immune toxin antibody conjugate (ITAC) solutions. The firm was founded by Zhu Zhong Yuan on July 3, 2019, and its main offices are situated in Shanghai, China.
Can you invest in Duality Biotherapeutics, Inc.?
Yes. Duality Biotherapeutics, Inc. trades publicly on HKSE as 9606.HK.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Duality Biotherapeutics, Inc.
Detailed equity research is provided by MarketSnap.